Community Oncology Alliance's (COA's) executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care.
Community Oncology Alliance's executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care. According to Okon, the proposed rule would have lowered drug prices for patients by ensuring they receive the benefit of negotiated drug discounts. By nixing the proposed rule, the administration has handed a gift to pharmacy benefit managers (PBMs).
In the original plan’s announcement, President Donald Trump and HHS Secretary Alex Azar acknowledged that “nearly every drug company taking a January 2019 price increase announced that all of the increase was being paid to PBMs or insurers as rebates.”
Read the full press release.
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More